DYAX – I don't even know what the story on the drug is.
The DX-88 story is long and tortuous. Throughout 2004, DYAX tried to scam investors into believing the FDA would approve DX-88 based on only the phase-2 results (#msg-5061316). GENZ once owned half of the DX-88 program, but they gave up their stake in the program for essentially nothing.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”